Marotta Asset Management Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Marotta Asset Management cut its position in Novo Nordisk A/S (NYSE:NVO) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,088 shares of the company’s stock after selling 565 shares during the period. Marotta Asset Management’s holdings in Novo Nordisk A/S were worth $1,408,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Hawaiian Bank raised its holdings in Novo Nordisk A/S by 30.3% during the fourth quarter. First Hawaiian Bank now owns 22,259 shares of the company’s stock worth $1,915,000 after purchasing an additional 5,171 shares in the last quarter. Range Financial Group LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $857,000. One Wealth Capital Management LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at $438,000. Diversified Trust Co boosted its stake in Novo Nordisk A/S by 13.9% in the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock valued at $279,000 after acquiring an additional 395 shares in the last quarter. Finally, Norman Fields Gottscho Capital Management LLC increased its position in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Trading Up 1.3 %

NVO stock traded up $1.15 during midday trading on Friday, hitting $86.79. The stock had a trading volume of 1,640,341 shares, compared to its average volume of 6,493,137. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The firm has a market cap of $389.47 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company’s 50-day moving average price is $100.86 and its 200 day moving average price is $119.79. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.